News

Dr Reddy’s ties up with RDIF for Corona vaccine Sputnik V

Dr Reddy’s ties up with RDIF

The Russian Direct Investment Fund (RDIF) has tied up with India’s Dr. Reddy’s Laboratories to conduct the clinical trials of Sputnik V vaccine in India.

If the vaccine gets approved from the Indian regulators, Russia will supply 100 million doses of the Covid-19 vaccine. As per a MINT report, deliveries could begin as early as December this year.

“India is among the most severely impacted countries from covid-19, and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against covid-19,” RDIF chief executive officer Kirill Dmitriev was quoted as saying by the report.

Also read: Dr. Reddy’s expands portfolio with acquisition of ANDA in US

The development comes at a time when India has become second worst affected country after the United States as Covid-19 tally has crossed 5 million mark. The average number of daily cases stands at around 90,000.

Responding to the development, G V Prasad, CEO Dr Reddy’s, was quoted as saying, “The Phase I and II results have shown promise, and we will be conducting Phase-III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India.”

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on


Most Popular

SUBSCRIBE OUR NEWSLETTER
200000+ Subscribers read it every day.
Subscribe Newsletter
To Top